Skip to main
OBIO
OBIO logo

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. demonstrates a positive outlook supported by significant operational advancements, including a protocol update that exponentially increases the potential patient pool for its treatments, targeting 500 enrollments by mid-2026. Additionally, the company's research and development (R&D) expenses rose by 21%, reflecting a committed investment in innovation, particularly highlighted by recent publications showcasing the effectiveness of its AVIM therapy on cardiac function. With a strategic focus on partnerships to drive commercialization, the company positions itself well for future growth in the biomedical sector.

Bears say

Orchestra BioMed Holdings Inc. has faced ongoing operating losses since its inception, raising concerns about its potential for achieving consistent profitability. The lengthy and costly nature of clinical trials for its product candidates, combined with the uncertainty of their safety and efficacy outcomes, further exacerbates financial risks. Additionally, the possibility that key intellectual property may not adequately protect its products introduces further challenges to its long-term viability and revenue generation potential.

OBIO has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 4 analysts, OBIO has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.